ASH 2010 Homepage Header

Oncology NEWS International reports on critical information from the American Society of Hematology's 52nd annual meeting.

• Rituximab instead of ‘watch and wait’ policy in asymptomatic follicular lymphoma causes controversy

• Ofatumumab generates high response rates in refractory CLL

• Industry update: Early-stage trials establish pathways for new treatment agents

 More Coverage from ASH 2010